IP Library › Granted Patent US 11,261,274
Granted Patent B2
US 11,261,274 · App. 16/693,077 · Granted Mar 1, 2022

Polymer particles

Inventors: Steve Plotkin (Tustin, CA); Gregory M. Cruise (Rancho Santa Margarita, CA); Edward Michael Keeley (Huntington Beach, CA); Renee Yu (Tustin, CA); Clayton Harris (Irvine, CA)
Assignee: Terumo Corporation
C08F220/28A61K9/0019A61K9/146A61K9/5026A61K31/704A61K47/32A61L24/0015A61L24/06C08F16/06C08F20/28C08F20/38C08F20/56C08F22/385C08F220/10C08F220/38C08F290/062C08G65/33324A61L2300/418C08F220/282C08F220/382Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,261,274
App. No.
16/693,077
Granted
Mar 1, 2022
Kind
B2
Abstract

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents.

Claims (41)

1. A polymer particle comprising:

a poly(ethylene glycol) diacrylamide macromer;

a first monomer; and

a second monomer configured to allow binding of positively charged drugs, wherein the second monomer is selected from acrylic acid, 3-sulfopropyl acrylate, 3-sulfopropyl methacrylate, a salt thereof, or a combination thereof;

wherein the polymer particle is spherical.

2. The polymer particle of claim 1 , wherein the polymer particle has a diameter between about 40 μm and about 1,200 μm.

3. The polymer particle of claim 1 , wherein the polymer particle has a diameter less than about 1,200 μm.

4. The polymer particle of claim 1 , wherein the first monomer includes a functional group.

5. The polymer particle of claim 4 , wherein the functional group is an acrylate, an acrylamide, a methacrylate, or a methacrylamide.

6. The polymer particle of claim 1 , wherein the first monomer glycerol monomethacrylate, amino ethyl methacrylate, amino propyl methacrylate, or a combination thereof.

7. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide is poly(ethylene glycol) diacrylamide 10,000.

8. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide macromer is at a concentration of about 28% w/w.

9. The polymer particle of claim 1 , wherein the first monomer is amino ethyl methacrylate, amino propyl methacrylate, or a combination thereof.

10. A polymer particle comprising:

a poly(ethylene glycol) macromer,

a first monomer; and

a second monomer configured allow binding of negatively charged drugs, wherein the second monomer is selected from amino ethyl methacrylate, 2-amino ethyl methacrylate, amino propyl methacrylamide, a salt thereof, or a combination thereof;

wherein the polymer particle is spherical.

11. The polymer particle of claim 10 , wherein the polymer particle has a diameter between about 40 μm and about 1,200 μm.

12. The polymer particle of claim 10 , wherein the polymer particle has a diameter less than about 1,200 μm.

13. The polymer particle of claim 10 , wherein the first monomer includes a functional group.

14. The polymer particle of claim 13 , wherein the functional group is an acrylate, an acrylamide, a methacrylate, or a methacrylamide.

15. The polymer particle of claim 10 , wherein the first monomer is glycerol monomethacrylate, 3-sulfopropyl acrylate, or a combination thereof.

16. The polymer particle of claim 10 , wherein the poly(ethylene glycol) macromer is poly(ethylene glycol) diacrylamide.

17. The polymer particle of claim 16 , wherein the poly(ethylene glycol) diacrylamide is poly(ethylene glycol) diacrylamide 10,000.

18. The polymer particle of claim 10 , wherein the poly(ethylene glycol) macromer is at a concentration of about 28% w/w.

19. A kit comprising:

a plurality of polymer particles in a container,

wherein the plurality of polymer particles comprise a reaction product of:

a poly(ethylene glycol) diacrylamide macromer;

a first monomer; and

a second monomer configured to allow binding of positively charged drugs,

wherein the second monomer is selected from acrylic acid, methacrylic acid, 3-sulfopropyl acrylate, 3-sulfopropyl methacrylate, a salt thereof, or a combination thereof;

wherein the plurality of polymer particles are spherical and have a diameter less than about 1,200 μm.

20. A kit comprising:

a plurality of polymer particles in a container,

wherein the plurality of polymer particles comprise a reaction product of:

a poly(ethylene glycol) macromer;

a first monomer; and

a second monomer configured allow binding of negatively charged drugs, wherein the second monomer is selected from amino ethyl methacrylate, 2-amino ethyl methacrylate, amino propyl methacrylamide, a salt thereof, or a combination thereof;

wherein the plurality of polymer particles are spherical and have a diameter less than about 1,200 μm.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2019
From: PLOTKIN, STEVE; CRUISE, GREGORY M.; KEELEY, EDWARD MICHAEL; YU, RENEE; HARRIS, CLAYTON
To: MICROVENTION, INC.
Reel/Frame 051093/0219 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2019
From: MICROVENTION, INC.
To: TERUMO CORPORATION
Reel/Frame 051093/0260 →
Continuity (5)
Continuation 16147225 · Sep 28, 2018
Continuation 15604529 · May 24, 2017
Continuation 14536394 · Nov 7, 2014
Provisional Application 61902020 · Nov 8, 2013
Related Publication 20200131287A1 · Apr 30, 2020
Cited By (2)
US 12,364,786 US 12,447,228